Stifel Nicolaus reissued their buy rating on shares of AnaptysBio, Inc. (NASDAQ:ANAB) in a research note published on Tuesday morning. They currently have a $35.00 price objective on the biotechnology company’s stock.
ANAB has been the subject of several other reports. Zacks Investment Research raised AnaptysBio from a hold rating to a buy rating and set a $34.00 price target for the company in a report on Thursday, September 7th. Credit Suisse Group raised their price target on AnaptysBio from $34.00 to $38.00 and gave the company an outperform rating in a report on Friday, August 25th. Finally, Robert W. Baird initiated coverage on AnaptysBio in a report on Monday, July 10th. They issued an outperform rating and a $36.00 price target for the company. Six research analysts have rated the stock with a buy rating, The company currently has an average rating of Buy and an average price target of $36.00.
Shares of AnaptysBio (NASDAQ:ANAB) opened at 32.09 on Tuesday. AnaptysBio has a 52-week low of $15.17 and a 52-week high of $33.58. The stock’s market capitalization is $652.77 million. The stock has a 50 day moving average price of $32.40 and a 200-day moving average price of $24.79.
AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.29. The company had revenue of $7.00 million for the quarter, compared to analyst estimates of $3.45 million. On average, equities research analysts anticipate that AnaptysBio will post ($1.96) EPS for the current fiscal year.
WARNING: This article was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.tickerreport.com/banking-finance/2888025/anaptysbio-inc-anab-receives-buy-rating-from-stifel-nicolaus.html.
In other news, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of the firm’s stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $24.35, for a total value of $901,924.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Holdings A/S Novo sold 70,706 shares of the firm’s stock in a transaction that occurred on Thursday, August 3rd. The shares were sold at an average price of $23.31, for a total value of $1,648,156.86. Following the completion of the sale, the insider now directly owns 3,009,949 shares of the company’s stock, valued at $70,161,911.19. The disclosure for this sale can be found here. Insiders sold a total of 1,133,940 shares of company stock valued at $24,223,316 over the last three months.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Frazier Management LLC acquired a new stake in shares of AnaptysBio in the 1st quarter valued at approximately $102,354,000. Perceptive Advisors LLC acquired a new stake in shares of AnaptysBio in the 1st quarter valued at approximately $24,474,000. Artal Group S.A. lifted its holdings in shares of AnaptysBio by 459.4% in the 2nd quarter. Artal Group S.A. now owns 250,000 shares of the biotechnology company’s stock valued at $5,983,000 after buying an additional 205,310 shares during the period. Marshall Wace North America L.P. acquired a new stake in shares of AnaptysBio in the 1st quarter valued at approximately $6,924,000. Finally, MARSHALL WACE ASIA Ltd acquired a new stake in shares of AnaptysBio in the 1st quarter valued at approximately $6,924,000. 71.35% of the stock is owned by institutional investors and hedge funds.
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.